Endo Pharmaceuticals Inc. v. Impax Laboratories Inc.
1:07-cv-00731
Overview
Parties
Defendant
Impax Laboratories Inc. Operating Company
Represented By
1 Attorneys ListedMorris James LLP
500 Delaware Avenue, Suite 1500, P.O. Box 2306
Endo Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Penwest Pharmaceuticals Co. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 18 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,662,933 A Asserted | US Continuation / Sibling | View Official Patent → |
| π¨π¦ Canada | CA 002208230 A | Canada Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2208230 C | Canada Counterpart | View Official Patent → |
| π―π΅ Japan | JP 51763797 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 3250737 B2 | Japan Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 1997016172 A1 | PCT World Application | View Official Patent → |
| π©πͺ Germany | DE 69638364 T | Germany Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 96,940,352 A | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 804,166 B1 | European Counterpart (EP) | View Official Patent → |
| π°π· South Korea | KR 1019970704 | South Korea Counterpart | View Official Patent → |
| π°π· South Korea | KR 100264024 B1 | South Korea Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 10,178,632 A | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,286,796 A3 | European Counterpart (EP) | View Official Patent → |
| πΊπΈ United States | US 5,958,456 A | US Continuation / Sibling | View Official Patent → |
| π°π· South Korea | KR 1020000000 | South Korea Counterpart | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5662933
Controlled release formulation (albuterol)
|
Filed: 1995-11-03
Issued: 1997-09-02
|
Expired (Term Ended)
Expires: 2015-11-03
|
|
|
US5958456
Controlled release formulation (albuterol)
|
Filed: 1997-07-01
Issued: 1999-09-28
|
Expired (Term Ended)
Expires: 2017-07-01
|
|
|
US7276250
Sustained release formulations of oxymorphone
|
Filed: 2002-07-03
Issued: 2007-10-02
|
Expired (Term Ended)
+216d PTA
Expires: 2023-02-04
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
20
Dispositive
11
Granted
0
Denied
1
Pending / Review
15
Motions by Category
Key Dispositive Motions & Rulings